Zero Knowledge and High Interest in the Use of Long-acting Injectable Pre-exposure Prophylaxis (PrEP) Among Adolescent Men Who Have Sex with Men and Transgender Women in Two Capital Cities in Brazil

Overview

Journal BMC Public Health

Publisher Biomed Central

Specialty Public Health

Date 2022 Sep 12

PMID 36096758

Authors

Leo Pedrana

Laio Magno

Eliana Miura Zucchi

Luis Augusto Vasconcelos da Silva

Dulce Ferraz

Alexandre Grangeiro

Marcelo Castellanos

Sandra Assis Brasil

Ines Dourado

Affiliations

Soon will be listed here.

Abstract

Background: Adolescent men who have sex with men (aMSM) and transgender women (aTGW) are affected disproportionately by human immunodeficiency virus (HIV) infection. Although new methods of pre-exposure prophylaxis (PrEP), such as long-acting injectable (LAI-PrEP), have been approved by the Food and Drug Administration, their acceptability among aMSM/aTGW is not well known.

Methods: Forty-eight semi-structured interviews were conducted to assess the knowledge and interest in LAI-PrEP among aMSM/aTGW enrolled in a daily oral PrEP cohort from two capital cities of Brazil since 2019.

Results: Previous knowledge of LAI-PrEP remains scarce, but the high interest regarding its use has been reported. Interest in the use of LAI-PrEP is associated with eliminating the burden of daily responsibility or the risk of missing the necessary medications, lowering the costs of this method, increasing confidentiality, and decreasing the frequency of visiting PrEP clinics. The reported barriers to uptake included fear of injection, doubts on its effectiveness, side effects, and greater dependence on a health provider.

Conclusions: There is an urgent need to strengthen the preventive strategies against HIV infection among the youth, enhance their knowledge and those of healthcare providers, and offer safe and new options.

Citing Articles

Long-Acting Injectable Pre-Exposure Prophylaxis Perceptions and Preferences Among Transgender and Nonbinary Young Adults in the United States.

Gordon A, Haiken S, Murchison G, Agenor M, Hughto J, Nelson K Qual Health Res. 2024; 35(1):74-87.

PMID: 39095331 PMC: 11869390. DOI: 10.1177/10497323241265943.

HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study.

Psaros C, Goodman G, Lee J, Rice W, Kelley C, Oyedele T J Int AIDS Soc. 2024; 27(5):e26252.

PMID: 38783534 PMC: 11116478. DOI: 10.1002/jia2.26252.

Preference for long-acting injectable for ART and PrEP among people with and without HIV: a cross-sectional study in Argentina.

Sciannameo S, Zalazar V, Spadaccini L, Duarte M, Cahn P, Aristegui I Ther Adv Infect Dis. 2024; 11:20499361241228341.

PMID: 38380160 PMC: 10878205. DOI: 10.1177/20499361241228341.

Willingness to take long-acting injectable pre-exposure prophylaxis among men who have sex with men who participated in the CROPrEP study: a cross-sectional online study.

Liu Y, Chu Z, Wang H, Huang X, Chen Y, Wang H BMC Public Health. 2023; 23(1):2494.

PMID: 38093204 PMC: 10717110. DOI: 10.1186/s12889-023-17325-9.

High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy.

Raccagni A, Galli L, Lucente M, Candela C, Lolatto R, Trentacapilli B AIDS Behav. 2023; 28(3):907-911.

PMID: 37792228 DOI: 10.1007/s10461-023-04197-8.

References

Fisher C, Fried A, Puri L, Macapagal K, Mustanski B . "Free Testing and PrEP without Outing Myself to Parents:" Motivation to participate in oral and injectable PrEP clinical trials among adolescent men who have sex with men. PLoS One. 2018; 13(7):e0200560. PMC: 6059443. DOI: 10.1371/journal.pone.0200560. View

Hosek S, Landovitz R, Kapogiannis B, Siberry G, Rudy B, Rutledge B . Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States. JAMA Pediatr. 2017; 171(11):1063-1071. PMC: 5710370. DOI: 10.1001/jamapediatrics.2017.2007. View

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

Macapagal K, Nery-Hurwit M, Matson M, Crosby S, Greene G . Perspectives on and preferences for on-demand and long-acting PrEP among sexual and gender minority adolescents assigned male at birth. Sex Res Social Policy. 2021; 18(1):39-53. PMC: 7810244. DOI: 10.1007/s13178-020-00441-1. View

Crosland Guimaraes M, Kendall C, Magno L, Rocha G, Knauth D, Leal A . Comparing HIV risk-related behaviors between 2 RDS national samples of MSM in Brazil, 2009 and 2016. Medicine (Baltimore). 2018; 97(1S Suppl 1):S62-S68. PMC: 5991533. DOI: 10.1097/MD.0000000000009079. View

Saffier I, Kawa H, Harling G . A scoping review of prevalence, incidence and risk factors for HIV infection amongst young people in Brazil. BMC Infect Dis. 2017; 17(1):675. PMC: 5637257. DOI: 10.1186/s12879-017-2795-9. View

Ellison J, Berg J, Montgomery M, Tao J, Pashankar R, Mimiaga M . Next-Generation HIV Pre-Exposure Prophylaxis Preferences Among Men Who Have Sex with Men Taking Daily Oral Pre-Exposure Prophylaxis. AIDS Patient Care STDS. 2019; 33(11):482-491. PMC: 6839421. DOI: 10.1089/apc.2019.0093. View

Landovitz R, Donnell D, Clement M, Hanscom B, Cottle L, Coelho L . Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021; 385(7):595-608. PMC: 8448593. DOI: 10.1056/NEJMoa2101016. View

Coelho L, Torres T, Veloso V, Grinsztejn B, Jalil E, Wilson E . The Prevalence of HIV Among Men Who Have Sex With Men (MSM) and Young MSM in Latin America and the Caribbean: A Systematic Review. AIDS Behav. 2021; 25(10):3223-3237. DOI: 10.1007/s10461-021-03180-5. View

10.

Hill L, Maseko B, Chagomerana M, Hosseinipour M, Bekker L, Pettifor A . HIV risk, risk perception, and PrEP interest among adolescent girls and young women in Lilongwe, Malawi: operationalizing the PrEP cascade. J Int AIDS Soc. 2020; 23 Suppl 3:e25502. PMC: 7325511. DOI: 10.1002/jia2.25502. View

11.

Meyers K, Rodriguez K, Moeller R, Gratch I, Markowitz M, Halkitis P . High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy. PLoS One. 2014; 9(12):e114700. PMC: 4263701. DOI: 10.1371/journal.pone.0114700. View

12.

Meyers K, Wu Y, Brill A, Sandfort T, Golub S . To switch or not to switch: Intentions to switch to injectable PrEP among gay and bisexual men with at least twelve months oral PrEP experience. PLoS One. 2018; 13(7):e0200296. PMC: 6053164. DOI: 10.1371/journal.pone.0200296. View

13.

Rael C, Martinez M, Giguere R, Bockting W, MacCrate C, Mellman W . Transgender Women's Concerns and Preferences on Potential Future Long-Acting Biomedical HIV Prevention Strategies: The Case of Injections and Implanted Medication Delivery Devices (IMDDs). AIDS Behav. 2019; 24(5):1452-1462. PMC: 7181384. DOI: 10.1007/s10461-019-02703-5. View

14.

Montgomery E, Atujuna M, Krogstad E, Hartmann M, Ndwayana S, ORourke S . The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth. J Acquir Immune Defic Syndr. 2019; 80(5):542-550. PMC: 6426447. DOI: 10.1097/QAI.0000000000001960. View

15.

Magno L, Silva L, Veras M, Pereira-Santos M, Dourado I . Stigma and discrimination related to gender identity and vulnerability to HIV/AIDS among transgender women: a systematic review. Cad Saude Publica. 2019; 35(4):e00112718. DOI: 10.1590/0102-311X00112718. View

16.

Kerr L, Kendall C, Crosland Guimaraes M, Mota R, Veras M, Dourado I . HIV prevalence among men who have sex with men in Brazil: results of the 2nd national survey using respondent-driven sampling. Medicine (Baltimore). 2018; 97(1S Suppl 1):S9-S15. PMC: 5991534. DOI: 10.1097/MD.0000000000010573. View

17.

Patel R, Crane J, Lopez J, Chan P, Liu A, Tooba R . Pre-exposure prophylaxis for HIV prevention preferences among young adult African American men who have sex with men. PLoS One. 2018; 13(12):e0209484. PMC: 6310267. DOI: 10.1371/journal.pone.0209484. View

18.

Kerrigan D, Mantsios A, Grant R, Markowitz M, Defechereux P, La Mar M . Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States. AIDS Behav. 2018; 22(11):3540-3549. PMC: 6108948. DOI: 10.1007/s10461-017-2017-x. View

19.

Beymer M, Gildner J, Holloway I, Landovitz R . Acceptability of Injectable and On-Demand Pre-Exposure Prophylaxis Among an Online Sample of Young Men Who Have Sex with Men in California. LGBT Health. 2018; 5(6):341-349. PMC: 6145037. DOI: 10.1089/lgbt.2017.0244. View

20.

Golub S, Meyers K, Enemchukwu C . Perspectives and Recommendations From Lesbian, Gay, Bisexual, Transgender, and Queer/Questioning Youth of Color Regarding Engagement in Biomedical HIV Prevention. J Adolesc Health. 2019; 66(3):281-287. PMC: 7007846. DOI: 10.1016/j.jadohealth.2019.09.016. View